This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| FCGR3A | |
|---|---|
| Name | FCGR3A |
| Other names | CD16a |
| Location | Chromosome 1q23 |
| Products | Fc gamma receptor IIIa protein |
| Species | Homo sapiens |
FCGR3A FCGR3A encodes an activating low-affinity receptor for the Fc portion of immunoglobulin G, expressed primarily on natural killer cells, macrophages, and subsets of monocytes. It participates in antibody-dependent cellular cytotoxicity and immune complex clearance, influencing responses to pathogens, autoantibodies, and monoclonal antibody therapies. The receptor's function and polymorphic variants have been studied across immunology, oncology, rheumatology, and infectious disease contexts.
FCGR3A mediates effector functions through binding to the Fc region of IgG, enabling processes such as antibody-dependent cellular cytotoxicity and phagocytosis. It cooperates with signaling adaptors and surface molecules on natural killer cells and macrophages to trigger cytotoxic granule release and cytokine production, affecting outcomes in viral infections, parasitic infestations, and tumor surveillance. Studies intersect with findings from research institutions and trials involving immunotherapies at centers like Memorial Sloan Kettering Cancer Center, Mayo Clinic, Johns Hopkins University, Massachusetts General Hospital, and National Institutes of Health investigators. Observational and interventional work often references cohorts from Harvard Medical School, Stanford University, University of Oxford, University of Cambridge, and Imperial College London.
The FCGR3A gene encodes a glycosylated transmembrane protein with extracellular Ig-like domains that determine IgG subclass affinity and specificity. Expression is regulated at transcriptional and post-transcriptional levels in lineage-committed immune cells, with differential expression noted between peripheral blood and tissue-resident cells studied in datasets from The Cancer Genome Atlas, 1000 Genomes Project, GTEx, European Bioinformatics Institute, and Gene Expression Omnibus. Structural characterization has been informed by crystallography and cryo-EM studies conducted at facilities such as European Molecular Biology Laboratory, Max Planck Institute, Cold Spring Harbor Laboratory, and Riken. Comparative analyses reference immunoglobulin interactions explored at Scripps Research Institute, Weizmann Institute of Science, Karolinska Institutet, and Howard Hughes Medical Institute laboratories.
Polymorphisms in FCGR3A, notably the well-known Val158Phe substitution, influence receptor affinity for IgG and correlate with differential clinical responses. Population genetics and allele frequency data are reported by consortia and databases including 1000 Genomes Project, HapMap Project, Exome Aggregation Consortium, Genome Aggregation Database, and studies from research groups at Broad Institute, Wellcome Trust Sanger Institute, European Bioinformatics Institute, University of Washington, and Cold Spring Harbor Laboratory. Large-scale association studies and meta-analyses from teams at University of California, San Francisco, Yale University, University College London, Duke University, and University of Pennsylvania have investigated links between FCGR3A variants and outcomes in autoimmune disease, infection susceptibility, and therapeutic efficacy.
Alterations in FCGR3A function and genotype associate with clinical phenotypes across oncology, rheumatology, infectious diseases, and transplantation. Associations have been reported in clinical cohorts and trials coordinated by National Cancer Institute, European Society for Medical Oncology, American Society of Clinical Oncology, American College of Rheumatology, and multicenter studies involving Vanderbilt University Medical Center, Cleveland Clinic, Karolinska University Hospital, Mayo Clinic, and Hospital for Special Surgery. Diseases with reported links include non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, systemic lupus erythematosus, malaria, HIV infection, and antibody-mediated rejection in organ transplantation. Pharmacogenomic correlations have been evaluated in trials sponsored or analyzed by groups at Roche, Genentech, AstraZeneca, Pfizer, Novartis, and academic collaborators at Johns Hopkins University and University of Texas MD Anderson Cancer Center.
FCGR3A is a determinant of response to therapeutic monoclonal antibodies such as rituximab, trastuzumab, and cetuximab; genotype-guided studies have been undertaken by consortia and pharmaceutical companies including Roche, Genentech, Amgen, Regeneron, Bristol-Myers Squibb, and GlaxoSmithKline. Engineering of IgG Fc regions and development of Fc-optimized antibodies have been pursued at Sangamo Therapeutics, Xencor, Seattle Genetics, Seattle Biotech, and academic spinouts from Scripps Research Institute and University of Zurich. Pharmacogenomic guidelines have been discussed in panels convened by Clinical Pharmacogenetics Implementation Consortium, European Medicines Agency, Food and Drug Administration, and professional societies at American Society of Hematology and European League Against Rheumatism.
FCGR3A signals via association with immunoreceptor tyrosine-based activation motif-containing adaptors, engaging kinases and downstream pathways studied in signaling research at Cold Spring Harbor Laboratory, Max Planck Institute for Biochemistry, EMBL-EBI, Howard Hughes Medical Institute, and university labs at University of Chicago, Columbia University, Princeton University, Yale University, and Massachusetts Institute of Technology. Interaction networks include cross-talk with complement components and Fc receptor family members explored in proteomics consortia at ProteomeXchange, structural biology efforts at European Synchrotron Radiation Facility, and systems immunology teams at Institute Pasteur and Wellcome Sanger Institute. Signaling cascades implicate Src-family kinases, Syk, PI3K, and downstream adapters, with functional readouts assessed in translational studies from Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and National Institutes of Health laboratories.
Category:Human genes